Understand the source comparison
Peptides for Leaky Gut: Clinical vs Supplemental Comparison
BPC-157 Upregulates VEGF and FGF-2 for mucosal healing; restores tight junction protein synthesis 250–500 mcg/day Subcutaneous or oral Animal models (robust); human data (limited) Strongest mechanistic evidence for structural barrier repair; lacks Phase 3 huma
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Upregulates VEGF and FGF-2 for mucosal healing; restores tight junction protein synthesis
- 250–500 mcg/day
- Subcutaneous or oral
- Animal models (robust); human data (limited)
- Strongest mechanistic evidence for structural barrier repair; lacks Phase 3 human trials
- KPV
- Inhibits NF-κB to reduce inflammatory cytokine production; prevents tight junction degradation
- 500–1000 mcg/day
- Oral or enema
- Preclinical models (strong); human trials (minimal)
- Best for acute inflammatory flares targeting gut-specific pathways without systemic immune suppression
- Thymosin Alpha-1
- Modulates T-cell function; reduces systemic endotoxin burden indirectly via immune regulation
- 1.6–3.2 mg twice weekly
- Subcutaneous
- Clinical trials (hepatitis, sepsis); gut barrier data (indirect)
- Addresses immune dysregulation component; best combined with barrier-repair peptides like BPC-157
- L-Glutamine (amino acid)
- Serves as primary fuel source for enterocytes; supports baseline mucosal turnover
- 5–15 g/day
- Oral powder
- Human trials (mixed results); mechanism (well-established)
- Necessary but not sufficient—supports barrier function but does not reverse active tight junction degradation
- Collagen Peptides
- Provides glycine and proline for extracellular matrix synthesis; indirect barrier support
- 10–20 g/day
- Mechanism (plausible); direct gut data (weak)
- May support mucosal structure but lacks specific tight junction modulation; better as adjunct than monotherapy